Walden Biosciences Announces Positive Topline Data from Phase 1+ Clinical Study of WAL0921 in Development for Treatment of Kidney Diseases
15 avr. 2024 07h00 HE
|
Walden Biosciences, Inc.
Proprietary Human anti-suPAR Monoclonal Antibody Demonstrated Safety and Reduction of Circulating Free suPAR, a Cause of Kidney Disease Plans to Initiate Phase 2 Basket Study in Glomerular Kidney...
Walden Biosciences Expands Research Collaboration with the University of Michigan
10 janv. 2024 07h00 HE
|
Walden Biosciences, Inc.
Expands partnership with laboratory of world-leading physician-scientist, Salim Hayek, M.D. Includes biomarker analysis from Walden’s Phase 1+ clinical study with Walden’s humanized anti-suPAR...
Walden Biosciences to Host Virtual Event on November 14, 2023 “Transforming the Treatment Landscape of Chronic Kidney Disease”
07 nov. 2023 07h00 HE
|
Walden Biosciences, Inc.
Virtual event to include overview of Walden’s development programs and fireside chats highlighting the CKD landscape with Key Opinion Leaders Webcast to begin at 11:00 AM EST CAMBRIDGE, Mass., Nov. ...
Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of WAL0921, in Development for Treatment of Chronic Kidney Diseases
05 juin 2023 07h48 HE
|
Walden Biosciences, Inc.
Trial to Evaluate Proprietary Human anti-suPAR Monoclonal Antibody for Safety, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers Expects to Complete Enrollment by Year End 2023 CAMBRIDGE,...
Walden Biosciences Promotes Curt Dewan, CFA to Chief Financial Officer
05 avr. 2023 07h00 HE
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...
Walden Biosciences Announces Presentation at the Oppenheimer 33rd Annual Healthcare Conference
09 mars 2023 07h00 HE
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...
Walden Biosciences To Present at 5th Annual Chronic Kidney Disease Drug Development Summit
08 mars 2023 07h00 HE
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...
Walden Biosciences Announces Presentation at Antibody Engineering and Therapeutics Conference 2022
02 déc. 2022 07h00 HE
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...
Walden Biosciences Announces Participation at October Investor Conferences
13 oct. 2022 07h00 HE
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...
Walden Biosciences Appoints Peter Guest Linde, M.D. as Chief Medical Officer
11 oct. 2022 07h00 HE
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...